Bioidentical Hormones vs Synthetic HRT: What's the Difference?

What Are Bioidentical Hormones?

Bioidentical hormones — also called body identical hormones — are molecules that are chemically identical to the hormones your body produces naturally. The three main types used in menopause care are:

• Estradiol (E2) — the primary oestrogen produced by the ovaries
• Progesterone — the natural form, as opposed to synthetic progestogens
• Testosterone — used off-label for libido and energy in some women

The term "bioidentical" refers to molecular structure, not to where the hormone comes from. Most bioidentical oestrogens and progesterone used in regulated medicines are derived from plant sources (typically wild yam or soy) and then processed in a laboratory to match the human hormone precisely.

Key point: "Bioidentical" is a structural description, not a marketing claim. Regulated bioidentical products — such as 17β-oestradiol patches, gels, and micronised progesterone capsules — are licensed medicines with robust clinical data.

What Are Synthetic Hormones?

Synthetic hormones are modified versions of natural hormones. The modifications are deliberate: they allow a compound to be patented, improve stability, or change how the body absorbs it. Common examples include:

• Conjugated equine oestrogens (CEE) — a mixture of oestrogens derived from pregnant mare urine, used in brands like Premarin
• Medroxyprogesterone acetate (MPA) — a synthetic progestogen used in Provera and combined HRT products like Prempro
• Norethisterone / Norgestrel — synthetic progestogens found in many combined HRT tablets

These are not identical to the hormones your body makes. They bind to hormone receptors and produce hormonal effects, but their metabolic behaviour can differ.

Why Does the Difference Matter? The WHI Study

In 2002, the Women's Health Initiative (WHI) published landmark findings that alarmed both clinicians and patients worldwide. The trial, involving over 16,000 postmenopausal women, found that combined HRT using conjugated equine oestrogens plus medroxyprogesterone acetate (CEE + MPA) was associated with increased risks of breast cancer, coronary heart disease, stroke, and blood clots.¹

The fallout was enormous. HRT prescriptions collapsed. Many women stopped therapy abruptly.

But here's what the initial headlines missed: the WHI studied one specific combination — CEE + MPA — not all hormone therapy. The arm of the study involving oestrogen-only therapy (in women who had had a hysterectomy) actually showed a reduced risk of breast cancer, and the risk profile differed meaningfully.

The WHI findings should not be generalised to all hormone formulations. The type of hormone, the route of delivery, and the timing of initiation all matter significantly.

The E3N Cohort: A Clearer Picture

The E3N cohort study, a large French prospective study of over 80,000 women, provided important comparative data on different HRT types.²

Key findings:

• Women using oestrogen combined with micronised progesterone (bioidentical progesterone) had no statistically significant increase in breast cancer risk compared to never-users after 5+ years of use
• Women using oestrogen combined with synthetic progestogens (such as MPA or norethisterone) showed a significantly higher breast cancer risk
• The type of progestogen — not oestrogen — appeared to be the key differentiating factor

This research, supported by subsequent observational studies, has contributed to a major rethink in menopause medicine. Many guidelines now distinguish between micronised progesterone and synthetic progestins when discussing risk profiles.

Bioidentical HRT vs Synthetic HRT: Side-by-Side

What About Compounded Bioidentical Hormones?

A separate category exists: compounded bioidentical hormones, which are custom-prepared mixtures made by compounding pharmacies. These are often marketed as personalised formulations based on saliva or blood hormone testing.

This is where the science gets complicated. Compounded preparations are not subject to the same regulatory oversight as licensed medicines. They are not standardised for potency, purity, or consistency. Major medical bodies — including the British Menopause Society, the Endocrine Society, and the International Menopause Society — do not recommend compounded bioidentical hormones as a first-line option because:

• Efficacy and safety data are lacking
• Dosing accuracy cannot be guaranteed
• Hormone saliva testing is unreliable for guiding therapy

This is an important distinction: regulated bioidentical HRT (like oestradiol gel + micronised progesterone) is evidence-based. Custom compounded bioidentical preparations are not the same thing.

Route of Delivery: Why It Matters Beyond the Molecule

The way hormone therapy enters your body affects its risk profile independently of whether it's bioidentical or synthetic.

Transdermal oestrogen (patches, gels, sprays) delivers oestradiol directly through the skin into the bloodstream, bypassing first-pass liver metabolism. This is associated with:

• Lower risk of venous thromboembolism (VTE / blood clots) compared to oral oestrogen
• Lower risk of stroke
• No significant effect on triglycerides

Oral oestrogen passes through the liver first, which changes how the body handles it and raises clotting factors.

Most current clinical guidelines recommend transdermal oestrogen as the preferred route, particularly for women with cardiovascular risk factors or those over 60.

What Singapore Women Should Know

Menopause is not a disease — it's a biological transition. But for many women, the symptoms (hot flushes, night sweats, vaginal dryness, brain fog, mood changes, joint pain, poor sleep) significantly reduce quality of life. Effective, evidence-based support exists.

In Singapore, both bioidentical and synthetic hormone preparations are available by prescription. The most current clinical guidance — including from the Singapore Menopause Society — favours individualised treatment decisions based on:

• Your symptom profile and severity
• Your personal medical and family history
• Your risk factors for cardiovascular disease, breast cancer, and osteoporosis
• Your preferences around delivery route and formulation

Hormone therapy is not one-size-fits-all. The right approach for you is best determined in conversation with a clinician who understands the nuances — not from generalised guidelines written before the E3N data existed.

Frequently Asked Questions

Q: Are bioidentical hormones safer than synthetic HRT?
A: The evidence suggests that micronised (bioidentical) progesterone carries a lower breast cancer risk signal than synthetic progestogens, based on observational data like the E3N cohort. Bioidentical oestradiol delivered transdermally also carries lower clot risk than oral oestrogens. However, "bioidentical" alone is not a safety guarantee — compounded preparations without regulatory oversight carry their own risks. Speak with your doctor about regulated options.

Q: Is bioidentical HRT the same as "natural" HRT?
A: The terms are often used interchangeably, but they mean different things. "Body identical" hormones are regulated medicines with a molecular structure matching your own hormones. "Natural" has no clinical definition and is sometimes used to market unregulated compounded products. Look for licensed medicines, not marketing language.

Q: What is the WHI study, and does it apply to bioidentical hormones?
A: The 2002 Women's Health Initiative trial studied a specific combination of conjugated equine oestrogens and medroxyprogesterone acetate (MPA) — neither of which is a bioidentical hormone. Its findings should not be extrapolated to all hormone therapy formulations. More recent research distinguishes clearly between HRT types.

Q: Can I get bioidentical HRT in Singapore?
A: Yes. Regulated bioidentical hormone medicines (oestradiol patches/gels and micronised progesterone) are available in Singapore by prescription from a qualified doctor.

Q: Should I stop HRT based on the WHI findings?
A: Do not stop any prescribed medication without consulting your doctor first. The WHI findings relate to a specific formulation and a specific population. Your doctor can review your current prescription in light of current evidence.

The Bottom Line

The evidence increasingly supports a meaningful distinction between hormone types and delivery routes. Micronised progesterone and transdermal oestradiol — both bioidentical, both regulated — have a more favourable risk profile in observational studies than their synthetic oral counterparts. The WHI findings, correctly understood, reflect the limitations of one specific formulation — not all hormone therapy.

If you're navigating perimenopause or menopause in Singapore and want to understand your options, the most valuable step is a structured conversation with a clinician who takes menopause seriously.

Ready to understand your hormones?
Zoey connects you with menopause-informed clinicians in Singapore for a thorough, personalised assessment — no guesswork, no one-size-fits-all prescriptions.
👉 Start your consultation at zoey.sg

References

1. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321–333.
2. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies. Breast Cancer Res Treat. 2008;107(1):103–111. (E3N cohort)